This agenda is still in development. All sessions and timings are subject to regular change at this time.
We're sorry, but we couldn't find any results that match your search criteria. Please try again with different keywords or filters.
Loading
Investment Summit
-
Indigo Ballroom, Hilton Bayfront HotelOpening remarks
-
Indigo Ballroom, Hilton Bayfront HotelGain a data-driven outlook on the current state of cell and gene therapy (CGT) investment. This keynote explores emerging trends, evolving investor priorities, and why early-stage innovation remains essential to sustaining industry growth
-
Indigo Ballroom, Hilton Bayfront HotelPanel: This discussion brings together leading VCs to dissect how decision criteria have evolved, what defines a “fundable” company in 2026, and how scientific, regulatory, and commercial factors intersect to shape valuation and deal momentum.
-
Indigo Ballroom, Hilton Bayfront HotelSpotlight: The road from concept to growth-stage financing is rarely straightforward. In this in-depth spotlight session, a biotech founder shares first-hand lessons from navigating multiple funding rounds, balancing scientific proof-of-concept with investor readiness, and leveraging non-dilutive opportunities along the way. Attendees will gain a practical view of how to build traction and credibility in a cautious capital market.
-
Refreshment & networking breakIndigo Ballroom, Hilton Bayfront Hotel
-
Indigo Ballroom, Hilton Bayfront HotelPanel: As market dynamics continue to shift, biotech should reconsider how they access capital. Traditional venture financing may not be suitable for every stage or strategic need. This session will explore the landscape of non-traditional financing models including secondary transactions, liquidity solutions for existing shareholders, royalty financing, and the increasing role of family offices and angel investors.
-
Indigo Ballroom, Hilton Bayfront HotelFireside Chat: Explore how investors are identifying value in the infrastructure behind advanced therapies, and why tools and tech providers may be an opportunity for long-term growth.
-
Indigo Ballroom, Hilton Bayfront HotelNetworking
-
Indigo Ballroom, Hilton Bayfront HotelFireside chat: Unpack why strong commercial acumen is just as important as scientific excellence in securing funding and scaling successfully.
Speakers
-
Indigo Ballroom, Hilton Bayfront HotelPanel: Evaluate cross-border opportunities, and what factors differentiate regions in building sustainable biotech ecosystems.
-
Indigo Ballroom, Hilton Bayfront HotelRoundtable: Investor only roundtable
-
Indigo Ballroom, Hilton Bayfront HotelRoundtable: Investor only roundtable session
-
Indigo Ballroom, Hilton Bayfront HotelRoundtable: Investor only roundtable
-
Indigo Ballroom, Hilton Bayfront HotelInvestor roundtable
)
)
)
)
)
)
)
Founders Forum
-
Room AWorkshop: Transform a Good Deck into a Compelling Case. Rapid, focused reviews reveal what hooks investors and what to cut.
-
Room AWorkshop: Build under pressure, not despite it. Secure capital, fortify your team, and make crisp decisions that keep growth compounding when resources are thin.
-
Room AWorkshop: Learn how to transform strategy into execution by building the operational backbone for sustainable growth. Discover the systems, processes, and culture that enable biotech startups to scale with precision and resilience.
-
Room AWorkshop: Explore how to position your biotech for sustained strategic success beyond early funding rounds. Learn to build partnerships, enhance commercial readiness, and plan long-term trajectories that accelerate growth and impact.
Women in Advanced Therapies Congress
-
Room D
-
Room D
- How representation in leadership impacts innovation, culture, and organisational performance
- The role of male allies in accelerating gender equity and creating systemic, long-term change
- Practical pathways for companies to improve representation across scientific, technical, and executive roles
-
Room DSpotlight: Discover strategies to address disparities in women’s health research, clinical trials, and access to care. Learn how policy, advocacy, and industry engagement can advance equity in health outcomes.
Speakers
-
Room DRoundtable: Explore how to build, maintain and leverage networks and mentorships to advance careers and influence your industry.
-
Room DRoundtable: Share approaches to recognise and overcome self-doubt while thriving in male-dominated spaces.
-
Room DRoundtable: Discuss how empathy, intuition and people skills can be leveraged as leadership strengths.
-
Room DRoundtable: Examine actionable steps to advance women into executive and board-level positions.
-
Room DRoundtable: Explore strategies for securing funding, support and recognition for women-led initiatives.
-
Room DRoundtable: Discuss realistic ways to prioritise well-being while pursuing career success.
-
Room DRoundtable: Explore strategies to close gaps in research, clinical trials and healthcare access for women
-
Room DRoundtable: Share experiences of unconventional career trajectories and how they can create leadership opportunities.
-
Room DRoundtable: Discuss how collaboration and mentorship can foster a supportive and empowering environment.
-
Room DRoundtable: Examine strategies for engaging everyone in advancing gender equality.
-
Communicating with cross cultural awarenessRoom DRoundtable: Coming soon
-
To be confirmedRoom DRoundtable: Coming soon
)
Super Plenary
-
Indigo Ballroom, Hilton Bayfront HotelThe Superplenary kicks off Advanced Therapies Week by bringing the global CGT community together for a shared moment of insight, context, and strategic alignment. This opening session takes stock of the field as it stands today, examining the scientific breakthroughs already achieved, the manufacturing and regulatory realities that define current practice, and the challenges around market access and patient impact. By providing a clear, high-level view of today’s landscape, the Superplenary sets the stage for the week’s forward-looking discussions and cross-functional collaborations.
)
Advanced Therapies Live
-
Theatre 5ATW HARDTalk cuts through the noise with candid, one-to-one conversations that tackle the toughest questions in advanced therapies. No scripts, no softball questions - just real leaders, real stories, and real insight.
-
Theatre 5In conversation with Kristin Hege, former SVP, BMS True leadership in biotech and pharma is built not just on expertise, but on sponsorship, visibility, and the power dynamics that shape who advances ...
-
Theatre 5Biotech is a field where progress is nonlinear, the stakes are immense, and “failure” is often just another word for iteration. In this interview, a leading biotech builder reflects on what it really ...
-
Theatre 5Hosted by Sharron Cox, Founder & Host, She Leads Podcast
Innovation Zone
-
Innovation ZoneBausch+Stroebel
-
Innovation ZoneABEC
-
Bracco
-
Innovation Zone
Cell therapy is rapidly transforming modern medicine, offering new hope for patients with cancer, autoimmune conditions, and genetic disorders. However, the development and manufacturing of these therapies demand reagents of uncompromising quality, consistency, and safety. Qkine’s new Cell Therapy Grade proteins address this critical need by delivering:
- Defined manufacturing standards – Produced under controlled conditions with full traceability and regulatory support documentation
- Enhanced quality attributes – High purity, animal origin-free, low endotoxin levels, and reduced host cell protein/DNA contamination
- Scalability for clinical workflows – Consistent performance from research-grade to therapy-grade materials, enabling seamless transition to GMP production
- Regulatory readiness – Comprehensive Certificates of Analysis (CoA), Safety Data Sheets (SDS), and technical dossiers to support IND and clinical submissions
-
Innovation ZoneVIVEbiotech
-
Innovation ZoneLentitek
-
Innovation ZoneKoerber
-
Innovation ZonePluristyx
-
Innovation ZoneHouston Gene Therapeutics
-
Innovation ZoneProBio
-
Innovation ZoneKiraGen Bio
-
Innovation ZoneAddition Therapeutics
-
Innovation ZoneNKILT Therapeutics
-
Innovation ZoneCREATe Therapeutics
-
Innovation ZoneComodo
-
Innovation ZoneCrafton Bio
-
Innovation ZoneTBC
-
Innovation ZoneTBC
)
Plenary
-
Theatre 1
-
Theatre 1
- Importance of building commercial infrastructure to scale beyond founder-led models.
- Clarity of messaging and the need to align communications with different stakeholder priorities.
- Strategic visibility and thought leadership to strengthen credibility and partnerships.
- Use of data and evidence—including patient-centric and real-world outcomes—to drive decision-making and market access.
- Early preparation and disciplined investment in systems, talent, and processes to support growth.
-
Theatre 1
-
Theatre 1Victoria Grey and Tom Whitehead share their experiences as patients and advocates navigating the complexities of advanced therapies. The conversation explores the real-world challenges of access, treatment logistics, and the decisions patients face, providing a candid look at the human impact of emerging CGT.
Chairperson
-
Theatre 1
The CGT field has achieved what once seemed impossible: the scientific capability to engineer sophisticated therapies with unprecedented precision. Yet as the pipeline grows, new challenges are emerging. FDA rejections are on the rise, quality lapses are more visible, and hard-won manufacturing advances don’t always translate into real-world access.
What does the next chapter of this rapidly evolving field look like? How do we continue to translate scientific breakthroughs into safe, accessible, and scalable therapies? Join our panel of leading experts as they explore these questions, highlighting strategies in regulatory navigation, quality assurance, manufacturing optimization, and collaborative approaches to ensure that the next generation of therapies reaches the patients who need them most.
Chairperson
)
)
)
)
)
)
Technology and Innovation
-
Theatre 1Fireside Chat: Make automation your force multiplier for CGT manufacturing. Faster, more consistent batches with real-time oversight and smarter integration.
-
Theatre 1Spotlight: Explore how automation is transforming cell therapy production. Learn strategies to optimize processes, improve reproducibility, and enable scalable manufacturing for external and internal operations.
-
Theatre 1Spotlight: Discover how automated systems can scale Advanced Therapy Medicinal Product (ATMP) production. Learn strategies for flexible, decentralized and centralized manufacturing that support diverse cell products and time-sensitive personalized medicine workflows.
-
Theatre 1Spotlight: Explore strategies for implementing automation in early development of advanced therapies. Learn how robotics and process automation can improve reproducibility, streamline workflows, and accelerate product development.
-
Theatre 1Spotlight: Discover how digital twins and data-driven strategies can optimize cell and gene therapy (CGT) manufacturing. Learn to enhance process efficiency, predict outcomes, and lay the foundation for intelligent, scalable facilities.
-
Theatre 1Fireside Chat: Learn how to design and operate a smart cell and gene therapy manufacturing facility. Explore strategies for integrating automation, optimizing processes, and preparing a workforce for advanced manufacturing demands.
-
Theatre 1Fireside Chat: Unlock the next wave of CGT with platforms that cut cycle time, scale cleanly, and lift your hit rate from model to patient.
-
Theatre 1Spotlight: Discover how enabling technologies and next-generation tooling can accelerate process development and manufacturing in cell and gene therapies. Learn to adopt tools that enhance efficiency, reproducibility, and product quality.
-
From days to hours: The closest you can get to real-time sterility testing for cell & gene therapiesTheatre 1
-
Theatre 1Spotlight: Learn how combining omics data with automation and advanced analytics can accelerate discovery and therapeutic design. Discover strategies to harness integrated datasets for more informed decision-making and optimized development workflows.
-
Theatre 1Panel: Discover how artificial intelligence can enhance research and development in cell and gene therapies. Learn strategies to leverage AI for predictive modelling, translational insights, and streamlined R&D workflows.
)
)
)
)
)
)
)
)
)
)
Development and Scale-up
-
Theatre 2Panel: Efficient technology transfer and scalable manufacturing are critical for moving advanced therapy programs from development to clinical and commercial stages.
Chairperson
Speakers (4)
-
Theatre 2Spotlight: Explore adaptable bioseparation strategies that streamline purification for viral and non-viral modalities while improving scalability, yield and cost efficiency in advanced therapies manufacturing.
-
Theatre 2Spotlight: Discover how novel cell, gene and nucleic acid modalities are scaled for commercial manufacturing with flexible, efficient platforms at this advanced therapies conference session.
-
Theatre 2Panel: Explore how gene therapies can move from bespoke pilots to sustainable, platform-scale modalities by optimizing manufacturing, supply chains, cost of goods and commercialization models while maintaining quality, potency and global patient access.
-
Theatre 2Spotlight: Explore new models that relieve CGT manufacturing bottlenecks, boosting throughput, efficiency and scalable high-quality cell and gene therapy production.
-
Theatre 2Fireside chat: Explore how to build GMP ready manufacturing frameworks that align quality systems, tech transfer and scalable processes for advanced therapies production.
)
)
)
)
)
)
)
)
)
)
)
)
Clinical and translational excellence
-
Theatre 3Fireside chat: Examine how emerging biotech organizations can design translational infrastructure that supports the progression from discovery research to first-in-human studies.
-
Theatre 3Spotlight: Explore practical ways to structure first-in-human and early phase CGT trials, balancing dose escalation, biomarker and PK PD readouts with manufacturing, regulatory and program readiness milestones.
-
Theatre 3Spotlight: Speakers share practical ways to interpret heterogeneous early trial data across diverse patient populations and turn those translational insights into smarter dose selection, study design and go-forward decisions.
-
Theatre 3Fireside chat: Experts unpack how smarter model selection, dose and safety frameworks, and mechanistic insights can close the gap between animal data and human outcomes in advanced therapy programs.
-
Theatre 3
-
Theatre 3Spotlight: Discover collaborative models that unite academia, industry and translational partners to speed cell and gene therapy translation at this advanced therapies conference session.
-
Theatre 3Panel: Explore what truly trial-ready looks like in 2026, from aligning preclinical and translational data with dose, biomarker and safety requirements to building workflows that de-risk first-in-human studies and speed early clinical decisions.
-
Theatre 3Fireside chat: Experts share practical ways to structure early cell and gene therapy trials that balance safety, dose and biomarker strategy with regulatory expectations and translational predictivity.
-
Theatre 3Spotlight: Examine how to define endpoints that truly capture therapeutic impact in advanced therapies, linking biomarker strategy, dose and safety planning, patient variability and analytic methods into a coherent framework for reliable clinical insight.
-
Theatre 3Spotlight: Speakers compare solid tumor focused modalities through mechanism of action, tumor biology, dosing, biomarker strategy, manufacturing and delivery constraints so teams can make structured, early clinical modality choices with stronger predictive validity.
)
)
)
)
)
)
)
)
Commercial strategy and global access
-
Theatre 4Fireside chat: Discover how academic industry partnerships accelerate advanced therapies translation with effective models for governance, funding and IP at this conference session.
-
Theatre 4Panel: Dive into how to build viable cell and gene therapy commercial models, balancing pricing, access, manufacturing costs and investor expectations in this conference session.
-
Theatre 4Fireside chat: Discover cross-sector partnerships that align academic, industry and investor goals to accelerate advanced therapies from research to commercialization.
-
Theatre 4Spotlight: Explore how end-to-end cell therapy supply chain solutions, from raw materials to patient delivery, support scalable, compliant commercialization at this cell and gene therapy conference session.
-
Theatre 4Spotlight: Compare CDMO partnerships and in house manufacturing for cost, control and scalability in advanced therapies at this cell and gene therapy conference session.
-
Theatre 4Fireside chat: Explore how strategic CDMO partnerships accelerate cell and gene therapy development, improving scalability, tech transfer and regulatory readiness in this session.
-
Theatre 4A tough economic and geopolitical landscape put pressure on innovator funding in 2023-24, the impact of which continues to reverberate through the industry. A hoped-for investor rebound has not yet materialized, instead venture capital investment into biotech continued to fall in early 2025, with public markets remaining selective and risk-averse. However, over a series of expert panel discussions with subject matter experts from CDMOs, innovators and investor organizations, it became clear that innovation cannot – and will not – wait for improved macro conditions.
-
Theatre 4
Fireside chat: Turn GMP sourcing into a strength, not a risk. Secure critical inputs, squeeze out bottlenecks, and build a supply chain that scales on schedule.
-
Theatre 4
Can decentralised and point of care models deliver speed without sacrificing quality or cost control? See how digital tools, modular sites, and closed systems make local manufacturing scale.
-
Theatre 4Spotlight: Turn your CDMO into a scale engine for CGT. Speed tech transfer, standardise quality, and compress time to clinic and launch.
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
Phacilitate.TV
-
ElevateBio: Coming soonPhacilitate.TV Studio
-
Bio-techne: Coming soonPhacilitate.TV Studio
-
Phacilitate.TV StudioLive Interview: An expert discussion on how supplier partnerships can stabilise quality, streamline GMP changeovers, and protect timelines as cell therapy manufacturing scales.Bio-techne
-
Phacilitate.TV StudioLive Interview: DMSO toxicity and variability can compromise both cells and patients. Learn how Pentahibe® DMSO-free and low-DMSO formulations support high recovery with cGMP consistency.
Chairperson
-
Assurea LLC: Coming soonPhacilitate.TV StudioAssurea LLC
-
Marken: Coming soonPhacilitate.TV Studio
)
)
Workshop
-
Theatre 2
Quality control (QC) remains one of the biggest constraints in scaling cell and gene therapy manufacturing — not only at release, but across the many in-process checkpoints that keep batches moving. These measurements are essential, yet today they’re slow, manual, and highly variable, creating delays long before a product ever reaches final testing. As developers work to increase batch throughput and move toward commercial readiness, the gap between what QC can handle and what manufacturing requires is widening.
Chairperson
-
Theatre 1Workshop: Join industry leaders for an engaging panel discussion exploring the future of end-to-end cell therapy manufacturing.Thermofisher
Speakers (5)
-
Shirley Bartido
Director Global Regulatory Affairs, Cell Therapy Oncology - Takeda -
Uma Lakshmipathy
Senior Director, Research & Development, Pharma Services Group - Thermo Fisher Scientific Inc. -
Namritha Ravinder
Director, Cell Biology - Thermo Fisher Scientific -
Shannon Eaker
Chief Technical Officer - Xcell Biosciences -
Holly Young
CMC and Cell Therapy Manufacturing Leader, Director University of California San Diego Advanced Cell Therapy Laboratory GMP Facility (UCSD ACTL) - University of California San Diego
-
-
Theatre 2
Workshop: Advancing CAR-T Cell Therapy Workflow with Novel Cell Selection and Non-Viral Delivery Methods
Speakers
-
Theatre 1
Workshop: Key Considerations in Preparing for Commercial Approval and Launch
Speakers (6)
-
Barry Oliver
Senior Principal - Dark Horse Consulting -
Kimberly Benton
Master Principal, Head of Regulatory - Dark Horse Consulting -
Robert Cantow
Practice Director, Supply Chain - Converge Consulting -
Eileen Choi
VP of Manufacturing Science and Technology - Dark Horse Consulting -
Heath Coats
Senior Principal, Head of Quality and Compliance - Dark Horse Consulting -
Joe Balleydier
Senior Practice Expert - Dark Horse Consulting
-
-
Theatre 2
Workshop: Details to be confirmed. This session will feature insights and discussions led by Accellix
-
Theatre 2
Workshop: Details to be confirmed. This session will feature insights and discussions led by Cytiva.
)
)
)
)
)
)
)
)
)
)
)
)
Advanced Therapies Live
-
Theatre 5Hosted by: Ben McLeod, Co-Founder & Jeff Martin, Co-Founder, Bio2Bedside
-
Theatre 5
-
Theatre 5Four leaders each share one bold prediction for the future of cell and gene therapy. Short, fast, and unfiltered, with live audience polling to vote on the most disruptive or exciting idea. A must-att ...
-
Theatre 5Advanced therapies are being reshaped by geopolitics, funding shifts, and emerging regional capabilities. U.S. momentum behind mRNA research is softening, creating downstream challenges for innovation ...
-
Theatre 5California hosts one of the world’s most vibrant and fast-growing advanced therapies ecosystems. This session will explore how local institution, from CIRM’s strategic funding and UCSD’s translational ...
-
Theatre 5Saudi Arabia is fast transforming into a major hub for advanced therapies—driven by the strategic imperatives of Vision 2030 and its National Biotechnology Strategy. With the recent launch of the firs ...
-
Theatre 5From translational research to commercial manufacturing, APAC’s ecosystem is increasingly integrated with global stakeholders. Learn how collaborations with international CDMOs, pharma, and research n ...
)
Innovation Zone
-
Innovation ZoneCharter Medical
-
Innovation ZoneAlpha Teknova
-
Innovation ZoneVitrafy
-
Innovation ZoneAlphalyse
-
Innovation ZoneTBC
-
Innovation ZoneTBC
-
Innovation ZoneTBC
-
Innovation ZoneTBC
-
Innovation ZoneNKore Therapeutics
-
Innovation ZoneMatricelf
-
Innovation ZoneForta Bio
-
Innovation ZoneBE Therapeutics
-
Innovation ZoneGlafabra Therapeutics
-
Innovation ZonePythera Therapeutics
-
Innovation ZoneZelig Therapeutics
-
Innovation ZoneTBC
-
Innovation ZoneErnexa Therapeutics
-
Innovation ZoneAlder Therapeutics / Xintela
-
Innovation ZoneD&P BioInnovations
-
Innovation ZoneTBC
Technology and Innovation
-
Theatre 1Spotlight
-
Theatre 1Spotlight: Explore strategies for reprogramming multiple immune cell types in vivo using a redosable CAR platform. Learn how this approach can enhance therapeutic precision, efficacy, and flexibility in targeting solid tumors.
-
Theatre 1Spotlight: Skip the ex vivo bottlenecks with in vivo engineering. Balance potency, safety, and trial design to bring cell therapy to more patients.
-
Theatre 1Spotlight: Discover how mRNA technology enables precise, transient, and controllable therapeutic interventions. Learn strategies to optimize delivery, expression, and functional outcomes for advanced therapies.
-
Theatre 1Spotlight: Learn how tools and technologies support process robustness and comparability from discovery through chemistry, manufacturing, and controls (CMC). Discover strategies to streamline development, ensure reproducibility, and de-risk scale-up.
-
Theatre 1
-
Theatre 1Spotlight: Discover how automated, closed, and simplified technology transfer systems support scalable cell therapy manufacturing. Learn strategies to improve process reproducibility, reduce errors, and accelerate scale-up.
-
Theatre 1Spotlight: Discover how Process Control 4.0 can integrate digital tools across the manufacturing lifecycle. Learn strategies to enhance data-driven decision-making, improve efficiency, and ensure consistent product quality.
-
Theatre 1Spotlight: Learn how digital twin technology can transform cell and gene therapy (CGT) manufacturing. Discover strategies to predict outcomes, optimize processes, and reduce variability across production workflows.
-
Theatre 1Panel: This panel explores strategies for designing robust analytical and quality control frameworks in cell and gene therapy manufacturing.
Chairperson
)
)
)
)
)
)
)
)
Development and Scale-up
-
Theatre 2Fireside chat: Delve into scalable viral vector manufacturing models that enhance throughput, quality and regulatory readiness at this advanced therapies conference session.
-
Theatre 2Spotlight: TBC
-
Theatre 2Fireside chat: Discover how to maintain product comparability across sites and phases with robust analytics, process control and risk management in CGT manufacturing.
-
Theatre 2Spotlight: Explore how allogeneic cell therapies can deliver long-term scalability through robust process design, donor strategy and quality systems in this session.
-
Theatre 2Spotlight: Dive into practical strategies to scale allogeneic cell therapy manufacturing, increasing throughput while maintaining product quality, consistency and compliance.
Speakers
-
Theatre 2Fireside chat: Compare autologous and allogeneic cell therapy manufacturing models for scalable, high-speed production while maintaining quality, consistency and compliance.
-
Theatre 2Spotlight: Explore how to overcome persistence challenges in allogeneic therapies using dosing, biomarkers and process design to deliver durable, scalable clinical impact.
-
Theatre 2Spotlight: Uncover proportional, staged control strategies that optimise resources, robustness and compliance in scalable advanced therapy manufacturing.
)
)
)
)
)
)
)
)
)
)
)
Clinical and translational excellence
-
Theatre 3Panel: Gain practical ways to embed patient perspectives into study design, endpoints, biomarkers and access frameworks so advanced therapies deliver clinically meaningful benefits for diverse real-world populations.
-
Theatre 3
-
Theatre 3Fireside chat: Explore how structured collaboration with patient advocacy groups can bring real world priorities into early trial design, endpoint and biomarker choices so CGT programs deliver more relevant and impactful early clinical outcomes.
-
Theatre 3Panel: Early stage developers explore practical ways to engage regulators proactively in cell and gene therapy, aligning preclinical and translational data, safety, dose and biomarker plans with evolving first-in-human and early trial expectations.
-
Theatre 3Spotlight: Gain practical frameworks to de-risk the clinical to commercial transition by tying clinical outcomes, dose and biomarker strategy, safety planning and manufacturing and delivery requirements into a scalable path to market.
-
Theatre 3Spotlight: Explora holistic framework for integrating commercial viability, quality assurance, and regulatory strategy into therapeutic design from the outset.
-
Theatre 3Panel: Explore how to fund and run global CGT clinical programs by aligning multinational trial design, translational data and regulatory strategies with the resources and operational models needed to move from discovery toward approval.
)
)
)
)
)
)
)
)
Commercial strategy and global access
-
Theatre 4Panel: Learn how payers evaluate cell and gene therapies, from evidence and long-term outcomes to pricing, value demonstration and innovative payment models in this CGT conference session.
-
Theatre 4
-
Theatre 4Fireside chat: Delve into global market access strategies for advanced therapies, from regulatory and payer requirements to launch sequencing and patient delivery in this conference session.
Chairperson
-
Theatre 4Fireside chat: Explore funding models, investor expectations and market trends shaping capital-intensive CGT development in this cell and gene therapy conference session.
-
Theatre 4Fireside chat: Learn how to fund advanced therapy programs from FIH to launch by aligning capital with milestones, risk and scalability at this advanced therapies conference session.
-
Theatre 4
)
)
)
)
)
)
)
)
Phacilitate.TV
-
Phacilitate.TV Studio
Showcase your announcements on Phacilitate.TV
Roundtable
-
Navigating the market access landscape and strategies for CGT commercialisationTheatre 2Roundtable: Coming soon
-
Overcoming access barriers: education & advocacy to expand patient reachTheatre 2Roundtable: Coming soon
-
Early development choices that enable seamless tech transferTheatre 2Roundtable: Coming soon
-
How to build a resilient supply chainTheatre 2Roundtable: Coming soon
-
Building the right workforceTheatre 2Roundtable: Coming soon
-
Designing your first clinical studyTheatre 2Roundtable: Coming soon
-
Creative ways to raise fundingTheatre 2Roundtable: Coming soon
-
Tariffs and trade - navigating cross-border manufacturing between US & RoWTheatre 2Roundtable: Coming soon
-
GMP for new modalitiesTheatre 2Roundtable: Coming soon
-
Partnering with patient organisations to influence policy & accelerate accessTheatre 2Roundtable: Coming soon
-
Protecting IP in a rapidly evolving ATMP landscapeTheatre 2Roundtable: Coming soon
-
Digitalising documentation for scalable, compliant CGT manufacturingTheatre 2Roundtable: Coming soon
-
Global access & equity: Expanding CGT availability beyond US/EU marketsTheatre 2Roundtable: Coming soon
-
Strategic asset prioritisation: Making the right pipeline bets in a resource-limited environmentTheatre 2Roundtable: Coming soon
Workshop
-
Theatre 1Are you ready to simplify your MSC workflow? Would you like a reliable, scale-up-ready solution to support your MSC therapy development? The road from early discovery to commercial manufacturing is ra ...Fujifilm
Chairperson
Speakers (4)
-
Theatre 2Details coming soonResilience
-
Theatre 2
This workshop slot is available for an industry sponsor to develop and curate a session as part of the Phacilitate Advanced Therapies Week agenda.
-
Theatre 1
Workshop: Navigating the Road Ahead for In Vivo CAR-T: An Interactive Roundtable
-
Theatre 1
This workshop slot is available for an industry sponsor to develop and curate a session as part of the Phacilitate Advanced Therapies Week agenda.
-
Theatre 2
This workshop slot is available for an industry sponsor to develop and curate a session as part of the Phacilitate Advanced Therapies Week agenda.
Technology and Innovation
-
Theatre 1Spotlight: Discover how SynCav1 gene therapy is being developed to address central nervous system (CNS) disorders. Learn strategies for targeted delivery, therapeutic design, and translational development in challenging neurological conditions.
-
Theatre 1Spotlight session: Route, dose, and monitor with confidence. Practical tactics to reach the right cells, manage adverse events, and execute lean trials in small populations.
-
Theatre 1Spotlight session: Explore the current landscape of cell therapies for type 1 diabetes. Learn how recent advances are shaping therapeutic strategies and bringing curative approaches closer to clinical reality.
Speakers
)
)
Development and Scale-up
-
Theatre 2Spotlight: Navigate novel cell sources and sourcing strategies that improve scalability, reproducibility and product quality in advanced therapies manufacturing.
Clinical and translational excellence
-
Theatre 3Spotlight: Explore practical frameworks for selecting and validating biomarkers and companion diagnostics that connect mechanism, dose, safety and patient stratification with endpoints to make CGT trials more precise and predictable.
-
Theatre 3Spotlight: Learn how to design and validate unbiased rcAAV assays with the sensitivity, specificity and reproducibility needed to support safety margins, regulatory expectations and confident clinical vector product release.
)
)
Special Interest Groups
-
Theatre 1Closed-door session: The Automation SIG unites experts from biopharma, technology, contract manufacturing, and academia to accelerate automation in cell and gene therapy (CGT) manufacturing, focusing on closed-system processing, digital integration, and workforce considerations to improve efficiency, consistency, and scalability.
-
Theatre 3Closed-door session: The Decentralized Manufacturing SIG unites stakeholders to explore scalable, resilient, and accessible models for cell therapy production. This group focuses on regulatory, technological, and quality challenges to advance collaborative, practical approaches worldwide.